Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

Pascual-Camps, Isabel; Hernández-Martínez, Pablo; Monje-Fernández, Laura; Dolz-Marco, Rosa; Gallego-Pinazo, Roberto; Wu, Lihteh; Arévalo, J Fernando; Díaz-Llopis, Manuel

doi:10.1186/s12348-014-0026-8

Journal of Ophthalmic Inflammation and Infection

Table 2 Summary of publications regarding the use of intravitreal infliximab

From: Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

Publications	Indication	Dosing	Number of cases	Main results
Theodossiadis et al. [17]	Neovascular AMD	2.0?mg/0.05?mL	3	BCVA improved from 20/200 to 20/40 after two monthly injections in case 1, from 20/200 to 20/70 after two bimonthly injections in case 2, and from 20/100 to 20/30 after two injections with a 3-month interval.
Giganti et al. [25]	Neovascular AMD	0.5?mg/0.05?mL	2	At week 12, BCVA had declined in three patients, and electroretinography and microperimetry had a decrease in all cases.
Giganti et al. [25]	DME	0.5?mg/0.05?mL	2
Arias et al. [26]	Neovascular AMD	2.0?mg/0.05 mL	4	At 3?months after a single injection, the BCVA change was ?18, +3, +4, and ?4 letters.
Arias et al. [26]	Neovascular AMD	2.0?mg/0.05 mL	4	Two cases developed severe intraocular inflammation.
Wu et al. [27]	DME	1.0?mg/0.05?mL	15	BCVA changed from 1.49 ? 0.58 to 1.38 ? 0.56 logMAR at 3?months in the 1 mg group.
Wu et al. [27]	DME	2.0?mg/0.10?mL	19	BCVA changed from 0.76 ? 0.5 to 1.03 ? 0.7 logMAR at 3?months in the 2 mg group, and 42% of cases developed severe intraocular inflammation.
Wu et al. [28]	Neovascular AMD	1.0?mg/0.05?mL	8	BCVA changed from 1.04 ? 0.2 to 1.06 ? 0.5 logMAR at 3?months in the 1 mg group.
		2.0?mg/0.10?mL	8	BCVA changed from 0.94 ? 0.5 at baseline to 0.85 ? 0.4 logMAR in the 2 mg infliximab group.
		2.0?mg/0.10?mL	8	37.5% of eyes developed severe intraocular inflammation.
Farvardin et al. [29],[30]	NIPU	1.5?mg/0.15?mL	7	BCVA changed from 1.37 ? 0.4 to 1.38 ? 0.4 logMAR at 6?months.
Farvardin et al. [29],[30]	NIPU	1.5?mg/0.15?mL	7	Vitreous haziness changed from 2.7 to 2.6 at 6?months.
Markomichelakis et al. [31]	Beh?et	1.0?mg/0.05?mL	15	BCVA changed from 0.74 to 0.3 logMAR at 30?days.
Markomichelakis et al. [31]	Beh?et	1.0?mg/0.05?mL	15	Intraocular inflammation decreased through day 30.
Wu et al. [32]	PCME	1.0?mg/0.10?mL	7	BCVA changed from 1.14 ? 0.6 to 0.51 ? 0.35 logMAR.
Wu et al. [32]	PCME	1.0?mg/0.10?mL	7	Mild intraocular inflammation was observed in one case.

AMD, age-related macular degeneration; DME, diabetic macular edema; NIPU, noninfectious posterior uveitis; PCME, pseudoaphakic cystoid macular edema; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimal angle of resolution.

Back to article page